Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tasly Pharmaceutical Co. Ltd.
Industry Sector: HealthTechnology
CEO: Jin Yong Cai
Number Of Employees: 10,958
Enterprise Value: $2,758,862,925
PE Ratio: 24.39
Exchange/Ticker 1: Shanghai:600535
Exchange/Ticker 2: N/A
Latest Market Cap: $3,206,562,851
BioCentury | Jan 4, 2022
Deals
Company Quick Takes: TandemAI seeded with $25M
Plus Sutro and Tasly deal, Sirnaomics raises and more
BioCentury | Jan 8, 2021
Finance
Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more
Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company
BioCentury | Oct 31, 2019
Financial News
I-Mab looks to fill gap in NASDAQ listings by Chinese players
BioCentury | Jun 25, 2019
Financial News
June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more
BioCentury | Oct 19, 2018
Clinical News
Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data
BioCentury | Oct 16, 2018
Clinical News
Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data
BioCentury | Aug 4, 2018
Finance
Hong Kong’s first wave
How Ascletis’ performance could affect up to 100 biotechs hoping to list on HKEX
Items per page:
1 - 10 of 54